An ongoing HCC clinical trial (NCT03329459) consists of determining the effects of combining FATE-NK100, an allogeneic donor-derived natural killer (NK) cell based cancer immunotherapy, with the anti-EGFR MoAb cetuximab. The gene discussed is EGFR; the disease is hepatocellular carcinoma.